Abstracts tagged "Vasculitis"

Abstract Number: 0510 • ACR Convergence 2020
Expression and Functional Activity of the Angiotensin II System in Temporal Artery Lesions from Patients with Giant Cell Arteritis
Marco A. Alba¹, Ester Planas-Rigol², Marc Corbera-Bellalta², Nekane Terrades-García³, Ana García-Martínez³, Sergio Prieto-González¹, Roser Alba-Rovira³, Georgina Espígol-Frigolé¹, Javier Marco-Hernández¹, Jose Hernández-Rodríguez¹, Josep M Grau⁴ and Maria C. Cid¹, ¹Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, Spain, ³Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, ⁴Department of Internal Medicine, Hospital Clínic and Fundació Cellex, University of Barcelona, Barcelona, Spain., Barcelona
Background/Purpose: Giant cell arteritis (GCA) is a large and medium size-vessel granulomatous vasculitis that predominantly affects the aorta and its major branches. The renin-angiotensin-aldosterone system…
Abstract Number: 1433 • ACR Convergence 2020
Thyroid Disease in ANCA-associated Vasculitis. a Population-based Study
Anna Wilding¹, Rona Smith², David Jayne³, Mårten Segelmark⁴ and Aladdin Mohammad⁵, ¹Lund University, Staffanstorp, Sweden, ²University of Cambridge, Cambridge, United Kingdom, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁴Lund University, Lund, ⁵Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: A higher incidence of thyroid disease has been seen in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We aim to assess the incidence…
Abstract Number: 1923 • ACR Convergence 2020
Angiographic Progression of Disease in Large-Vessel Vasculitis
Kaitlin Quinn¹, Himanshu Dashora², Mark Ahlman³, Elaine Novakovich² and Peter C. Grayson², ¹Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD
Background/Purpose: Angiography is essential to detect vascular disease in patients with large-vessel vasculitis (LVV). Guidelines differ on the role of periodic angiography to monitor patients…
Abstract Number: PP02 • ACR Convergence 2020
Low- and Hi-Tech Tools for Enhancing Patient-Hospital Care Team Communication in the Context of Rare Disease
Ida Hakkarinen¹, ¹Vasculitis Patient-Powered Research Network (VPPRN) / Member, Vasculitis Foundation, Greenbelt, MD
Background/Purpose: For over two years, I experienced a variety of disparate symptoms including: joint aches, sinus congestion, shortness of breath and chronic cough. An episode…
Abstract Number: 0403 • ACR Convergence 2020
Comparison of Immediate Post-Operative and Long-Term Outcomes in Aortitis and Non-Inflammatory Thoracic Aortic Aneurysms Undergoing Open Surgical Repair
Adam Mayer¹, Alexandra Sperry², Laarni Quimson³ and Rennie Rhee⁴, ¹University of Pennsylvania, Internal Medicine/Pediatrics Residency Program, Philadelphia, PA, ²Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology at the University of Chicago, Chicago, IL, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Around 2-12% of patients who undergo open thoracic aortic aneurysm repair are incidentally found to have aortitis on pathology. There is no standardized approach…
Abstract Number: 0511 • ACR Convergence 2020
ERAP1-mediated Immunogenicity and Immune-phenotypes in HLA-B51+ Behçet’s Disease Point to Pathogenic CD8 T Cell Effector Responses
Ann Cavers¹, Yesim Ozguler², Olivier Manches³, Arshed Al-Obeidi¹, Hua Zhong¹, Beatrix Ueberheide¹, Gülen Hatemi⁴, Matthias Kugler¹ and Johannes Nowatzky⁵, ¹NYU School of Medicine, New York, ²Istanbul University Cerrahpaşa Medical School, Istanbul, Turkey, ³Inserm, U 1209, Grenoble, France, ⁴Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, ⁵New York University School of Medicine, New York, NY
Background/Purpose: HLA-B51 is a definite risk factor for Behçet’s disease (BD). A coding variant of ERAP1, Hap10 – with low peptide-trimming activity – vastly potentiates…
Abstract Number: 1434 • ACR Convergence 2020
The Role of Sural Nerve Biopsy in the Diagnosis of Systemic Vasculitis – a Retrospective Study from Two Specialized Centres
Karl Gisslander¹, Lars Dahlin², Rona Smith³, David Jayne³ and Aladdin Mohammad⁴, ¹Lund University, Lund, Sweden, Lund, Sweden, ²Department of Translational Medicine – Hand Surgery, Lund University, Malmö, Sweden, Malmö, Sweden, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁴Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: Vasculitis of the peripheral nervous system is seen mainly in systemic vasculitis involving small and medium sized vessels and in cases of single-organ vasculitis…
Abstract Number: 1925 • ACR Convergence 2020
Ultrasound Follow-up Examination of Intima-Media-Thickness of the Temporal and Axillary Artery over Six Months in Patients with Newly Diagnosed Giant Cell Arteritis
Lara Burg¹, Peter Brossart², Charlotte Behning³ and Valentin Schaefer⁴, ¹Clinic for Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ³Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ⁴Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Ultrasound (US) plays an important role in diagnosis of giant cell arteritis (GCA). To date it is unknown how intima-media-thickness (IMT) of affected arteries…
Abstract Number: PP03 • ACR Convergence 2020
Connecting with Rheumatology Professionals and Thought Leaders Inspired the Creation of a New Program Focused on Relapsing Polychondritis (“RP”), a Rare Rheumatic Disease: Participating at ACR Annual Meetings Has Provided Exceptional Opportunities to Learn and Build Relationships
Nancy Linn¹, Catherine Bammert², David Bammert³ and Michael Linn⁴, ¹Relapsing Polychondritis Foundation, Palos Verdes Estates, CA, ²MD Anderson, Houston, TX, ³Relapsing Polychondritis Foundation, Houston, TX, ⁴Relapsing Polychondritis Foundation, New York, NY
Background/Purpose: In 2011, I was diagnosed with relapsing polychondritis ("RP"), a debilitating and sometimes fatal rheumatic disease that is characterized by inflammation of cartilage and…
Abstract Number: 0404 • ACR Convergence 2020
Isolated Aortitis: Single Centre Experience of Clinical Spectrum and Management
Nadia Ahmad¹, Ayna Verdiyeva², Raashid Luqmani² and Shirish Dubey², ¹Oxford University Hospitals NHS Foundation Trust, Reading, United Kingdom, ²Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Background/Purpose: Aortitis was previously regarded as a rare form of large vessel vasculitis (LVV), but is now increasingly being recognised. It may occur in the…
Abstract Number: 0514 • ACR Convergence 2020
Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study
Kaitlin Quinn¹, Himanshu Dashora², Mark Ahlman³, Elaine Novakovich² and Peter C. Grayson², ¹Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD
Background/Purpose: Two randomized controlled trials have demonstrated the clinical efficacy of tocilizumab for treatment of giant cell arteritis (GCA) (1,2). In these trials, response to…
Abstract Number: 1435 • ACR Convergence 2020
Prognostic Factors for Mononeuritis Multiplex Associated with ANCA-associated Vasculitis
Yutaro Hayashi¹, Satoshi Hama², Keisuke Izumi², Mari Ushikubo¹, Misako Konishi³, Yutaka Okano⁴ and Hisaji Ohshima², ¹Tokyo medical center, Tokyo, Japan, ²Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, tokyo, Japan, ³Tokyo medical center, toukyouto Meguroku, Japan, ⁴Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan
Background/Purpose: ANCA-associated vasculitis (AAV) sometimes presents mononeuritis multiplex which worsens the prognosis and activity of daily living in patients. This study aimed to determine theprognostic factorsand…
Abstract Number: 1928 • ACR Convergence 2020
Quantitative Ultrasound of Temporal, Axillary and Subclavian Arteries to Monitor Tocilizumab Treatment in Patients with Newly Diagnosed Giant Cell Arteritis: A 24 Week Analysis
Luca Seitz¹, Lisa Christ¹, Godehard Scholz¹, Fabian Lötscher¹, Jennifer Amsler¹, Florian Kollert¹, Stephan Reichenbach¹ and Peter Villiger¹, ¹Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland
Background/Purpose: Tocilizumab (TCZ) suppresses CRP. Thus, CRP cannot be used as a marker for disease activity in GCA patients treated with TCZ and monitoring of…
Abstract Number: 0406 • ACR Convergence 2020
Infliximab in Refractory Uveitis Due to Behçet’s Disease: Long Term Follow-up and Therapy Optimization. Multicenter Study of 103 Caucasian Patients
José Luis Martín-Varillas¹, Belén Atienza-Mateo², Vanesa Calvo-Río³, Emma Beltran-Catalan⁴, Alfredo Adan⁵, Marisa Hernandez Garfella⁶, Elia Valls-Pascual⁷, Agustín Sellas-Fernández⁸, N Ortego⁹, Alejandro Fonollosa¹⁰, Olga Maiz Alonso¹¹, Ignacio Torre¹², Cruz Fernández-Espartero¹³, Vega Jovani¹⁴, Diana Peiteado¹⁵, David Díaz Valle¹⁶, Susana Romero-Yuste¹⁷, Elena Aurrecoechea¹, Miriam García-Arias¹⁸, Miguel Ángel Caracuel¹⁹, Santos Insúa²⁰, Senén González-Suárez²¹, Amalia Sánchez Andrade²², Luis Francisco Linares²³, Alfredo J García González²⁴, Raquel Almodovar²⁵, Carmen Carrasco Cubero²⁶, María Alcalde Villar²⁷, C Fernandez-Carballido²⁸, Fred A Pages²⁹, Eva Peña Sainz-Pardo²⁴, Rosalia Demetrio-Pablo³, Santos Castañeda³⁰, Miguel Ángel González-Gay³¹, José Luis Hernández³ and Ricardo Blanco³, ¹Hospital Sierrallana, Torrelavega, Spain, ²Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁴Del Mar University Hospital, Barcelona, ⁵Hospital Clinic, Barcelona, Catalonia, Spain, ⁶H. Valencia, Valencia, Spain, ⁷H. Doctor Peset, Valencia, Spain, ⁸H. Vall d'Hebron, Barcelona, Spain, ⁹H. San Cecilio, Granada, Spain, ¹⁰H. de Cruces, Bilbao, Spain, ¹¹Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, ¹²Hospital Basurto, Bilbao, Spain, ¹³H. Mostoles, Madrid, Spain, ¹⁴H. Alicante, Alicante, Spain, ¹⁵Hospital La Paz - IdiPAZ, Madrid, Spain, ¹⁶H. Clínico San Carlos, Madrid, Spain, ¹⁷H Pontevedra, Coruna, Spain, ¹⁸H. La Princesa, Madrid, ¹⁹H.U. Reina Sofía, Córdoba, Spain, ²⁰H. Santiago de Compostela, Santiago de Compostela, Spain, ²¹H. Cabueñes, Gijón, Spain, ²²H. Lucus Augusti, Lugo, Spain, ²³Hospital de la Arrixaca, Murcia, ²⁴H. 12 de Octubre, Madrid, Spain, ²⁵Fundación Alcorcón University Hospital, Madrid, ²⁶H. Mérida, Mérida, Spain, ²⁷H. Severo Ochoa, Madrid, Spain, ²⁸H San Juan, Alicante, Spain, ²⁹H. Palencia, Palencia, Spain, ³⁰Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ³¹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Biologic therapy has improved prognosis of Behçet Disease (BD) uveitis. Although infliximab (IFX) is approved in Japan, most data in Caucasian patients comes from…
Abstract Number: 0517 • ACR Convergence 2020
Trends in the Incidence and Use of Diagnostic Modalities for Giant Cell Arteritis over Seven Decades: A Population-based Study
Thomas Garvey¹, Cynthia Crowson², Matthew J. Koster³ and Kenneth Warrington³, ¹Mayo Clinic Rochester, Apple Valley, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Diagnostic methods for giant cell arteritis (GCA) have evolved over recent decades, and large vessel imaging plays an increasing role in disease detection. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].